首页 > 最新文献

Endokrynologia Polska最新文献

英文 中文
Differential diagnosis of thyroid orbitopathy - diseases mimicking the presentation or activity of thyroid orbitopathy. 甲状腺眶病的鉴别诊断--模仿甲状腺眶病表现或活动的疾病。
Pub Date : 2024-01-01 DOI: 10.5603/ep.98156
Mariusz Nowak, Wojciech Nowak, Bogdan Marek, Beata Kos-Kudła, Lucyna Siemińska, Magdalena Londzin-Olesik, Dariusz Kajdaniuk

Thyroid orbitopathy (TO) is the most common cause of orbital tissue inflammation, accounting for about 60% of all orbital inflammations. The inflammatory activity and severity of TO should be diagnosed based on personal experience and according to standard diagnostic criteria. Magnetic resonance imaging (MRI) of the orbit is used not only to identify swelling and to differentiate inflammatory active from non-active TO, but also to exclude other pathologies, such as orbital tumours or vascular lesions. However, a group of diseases can mimic the clinical manifestations of TO, leading to serious diagnostic difficulties, especially when the patient has previously been diagnosed with a thyroid disorder. Diagnostic problems can be presented by cases of unilateral TO, unilateral or bilateral TO in patients with no previous or concomitant symptoms of thyroid disorders, lack of symptoms of eyelid retraction, divergent strabismus, diplopia as the only symptom of the disease, and history of increasing diplopia at the end of the day. The lack of visible efficacy of ongoing immunosuppressive treatment should also raise caution and lead to a differential diagnosis of TO. Differential diagnosis of TO and evaluation of its activity includes conditions leading to redness and/or swelling of the conjunctiva and/or eyelids, and other causes of ocular motility disorders and eye-setting disorders. In this paper, the authors review the most common diseases that can mimic TO or falsify the assessment of inflammatory activity of TO.

甲状腺眼眶病(TO)是眼眶组织炎症最常见的原因,约占眼眶炎症总数的60%。应根据个人经验和标准诊断标准来诊断甲状腺眼眶病的炎症活动和严重程度。眼眶磁共振成像(MRI)不仅可用于识别肿胀和区分炎症活动性和非活动性TO,还可用于排除其他病变,如眼眶肿瘤或血管病变。然而,有一组疾病可模仿TO的临床表现,从而导致严重的诊断困难,尤其是当患者之前曾被诊断为甲状腺疾病时。单侧TO、单侧或双侧TO的患者既往无甲状腺疾病症状或伴随甲状腺疾病症状、无眼睑后缩症状、分歧性斜视、复视是该病的唯一症状,以及在一天结束时复视加重的病史等病例都可能带来诊断问题。持续的免疫抑制治疗缺乏明显疗效也应引起警惕,并导致 TO 的鉴别诊断。TO 的鉴别诊断及其活动性评估包括导致结膜和/或眼睑发红和/或肿胀的疾病,以及导致眼球运动障碍和复视障碍的其他原因。在本文中,作者回顾了可模拟 TO 或伪造 TO 炎症活动评估的最常见疾病。
{"title":"Differential diagnosis of thyroid orbitopathy - diseases mimicking the presentation or activity of thyroid orbitopathy.","authors":"Mariusz Nowak, Wojciech Nowak, Bogdan Marek, Beata Kos-Kudła, Lucyna Siemińska, Magdalena Londzin-Olesik, Dariusz Kajdaniuk","doi":"10.5603/ep.98156","DOIUrl":"10.5603/ep.98156","url":null,"abstract":"<p><p>Thyroid orbitopathy (TO) is the most common cause of orbital tissue inflammation, accounting for about 60% of all orbital inflammations. The inflammatory activity and severity of TO should be diagnosed based on personal experience and according to standard diagnostic criteria. Magnetic resonance imaging (MRI) of the orbit is used not only to identify swelling and to differentiate inflammatory active from non-active TO, but also to exclude other pathologies, such as orbital tumours or vascular lesions. However, a group of diseases can mimic the clinical manifestations of TO, leading to serious diagnostic difficulties, especially when the patient has previously been diagnosed with a thyroid disorder. Diagnostic problems can be presented by cases of unilateral TO, unilateral or bilateral TO in patients with no previous or concomitant symptoms of thyroid disorders, lack of symptoms of eyelid retraction, divergent strabismus, diplopia as the only symptom of the disease, and history of increasing diplopia at the end of the day. The lack of visible efficacy of ongoing immunosuppressive treatment should also raise caution and lead to a differential diagnosis of TO. Differential diagnosis of TO and evaluation of its activity includes conditions leading to redness and/or swelling of the conjunctiva and/or eyelids, and other causes of ocular motility disorders and eye-setting disorders. In this paper, the authors review the most common diseases that can mimic TO or falsify the assessment of inflammatory activity of TO.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of steroid therapy in a 16-year-old girl observed for lymphocytic hypophysitis. 一名因淋巴细胞性肾上腺皮质功能减退症而就诊的 16 岁女孩接受类固醇治疗的效果。
Pub Date : 2024-01-01 DOI: 10.5603/ep.96770
Elżbieta Moszczyńska, Marta Baszyńska-Wilk, Patrycja Dasiewicz, Aleksandra Tutka, Anna Smorczewska-Kiljan, Magdalena Marszał, Iwona Pakuła-Kościesza

Not required for Clinical Vignette.

临床小论文不需要。
{"title":"Effect of steroid therapy in a 16-year-old girl observed for lymphocytic hypophysitis.","authors":"Elżbieta Moszczyńska, Marta Baszyńska-Wilk, Patrycja Dasiewicz, Aleksandra Tutka, Anna Smorczewska-Kiljan, Magdalena Marszał, Iwona Pakuła-Kościesza","doi":"10.5603/ep.96770","DOIUrl":"10.5603/ep.96770","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Height loss in postmenopausal women predicts multiple fractures in 10-year follow-up: results from the RAC-OST-POL study. 绝经后妇女身高下降可预测 10 年随访中的多发性骨折:RAC-OST-POL 研究结果。
Pub Date : 2024-01-01 DOI: 10.5603/ep.97226
Wojciech Pluskiewicz, Piotr Adamczyk, Aleksandra Werner, Malgorzata Bach, Bogna Drozdzowska

Introduction: In daily practice the diagnostic process for osteoporosis in elderly patients should also include physical assessment. The aim of the study was to verify the hypothesis that height loss (HL) predicts fracture incidence.

Material and methods: The study was performed in an epidemiological sample of postmenopausal women recruited in the RAC-OST-POL study. At baseline, data were collected in 978 postmenopausal women at a mean age of 66.48±7.6 years, and at 10-year follow-up 640 patients remained, with a mean age of 75.04 ± 6.95 years. Current height and HL were established in regard to maximal life height. Data on fracture incidence were gathered throughout the period of observation.

Results: During the follow-up period 190 osteoporotic fractures were noted. Ninety-one women had one fracture, and in 38 women, multiple fractures occurred. In the fractured and unfractured subgroups, HL was 5.45 ± 3.28 and 4.8 ± 3.56 cm, respectively, and differed significantly (p < 0.05). HL in subjects without fracture did not differ from those with one fracture (HL 4.8 ± 3.56 vs. 4.8 ± 2.66 cm, respectively). For patients with more than one fracture HL was 7.03 ± 4.06 cm and was significantly higher than in subjects with one or without any fracture (p < 0.01). Based on receiver operating characteristic (ROC) analysis, HL of 6 cm was identified as the cut-off point for high risk of multiple fractures.

Conclusion: HL of at least 6 cm is the predictor of multiple fractures in a prospective observation of a representative epidemiological female sample. Therefore, the measurement of HL should always be included in patients' assessments.

导言:在日常实践中,老年患者骨质疏松症的诊断过程也应包括体格评估。本研究旨在验证身高下降(HL)可预测骨折发生率的假设:这项研究是在 RAC-OST-POL 研究中招募的绝经后妇女的流行病学样本中进行的。基线研究收集了 978 名绝经后妇女的数据,她们的平均年龄为(66.48±7.6)岁,随访 10 年后仍有 640 名患者,她们的平均年龄为(75.04±6.95)岁。目前的身高和 HL 是根据最大寿命身高确定的。在整个观察期间收集了有关骨折发生率的数据:结果:在随访期间,共发现 190 例骨质疏松性骨折。结果:在随访期间,共发现 190 例骨质疏松性骨折,其中 91 例为一次骨折,38 例为多次骨折。骨折亚组和未骨折亚组的 HL 分别为 5.45 ± 3.28 厘米和 4.8 ± 3.56 厘米,差异显著(P < 0.05)。无骨折患者的 HL 与有一处骨折的患者没有差异(HL 分别为 4.8 ± 3.56 cm 与 4.8 ± 2.66 cm)。有一处以上骨折的患者的 HL 为 7.03 ± 4.06 厘米,明显高于有一处骨折或无任何骨折的患者(P < 0.01)。根据接收器操作特征(ROC)分析,HL为6厘米被确定为多发性骨折高风险的临界点:结论:在对具有代表性的流行病学女性样本的前瞻性观察中,至少 6 厘米的 HL 是多发性骨折的预测指标。因此,在对患者进行评估时,应始终测量 HL。
{"title":"Height loss in postmenopausal women predicts multiple fractures in 10-year follow-up: results from the RAC-OST-POL study.","authors":"Wojciech Pluskiewicz, Piotr Adamczyk, Aleksandra Werner, Malgorzata Bach, Bogna Drozdzowska","doi":"10.5603/ep.97226","DOIUrl":"10.5603/ep.97226","url":null,"abstract":"<p><strong>Introduction: </strong>In daily practice the diagnostic process for osteoporosis in elderly patients should also include physical assessment. The aim of the study was to verify the hypothesis that height loss (HL) predicts fracture incidence.</p><p><strong>Material and methods: </strong>The study was performed in an epidemiological sample of postmenopausal women recruited in the RAC-OST-POL study. At baseline, data were collected in 978 postmenopausal women at a mean age of 66.48±7.6 years, and at 10-year follow-up 640 patients remained, with a mean age of 75.04 ± 6.95 years. Current height and HL were established in regard to maximal life height. Data on fracture incidence were gathered throughout the period of observation.</p><p><strong>Results: </strong>During the follow-up period 190 osteoporotic fractures were noted. Ninety-one women had one fracture, and in 38 women, multiple fractures occurred. In the fractured and unfractured subgroups, HL was 5.45 ± 3.28 and 4.8 ± 3.56 cm, respectively, and differed significantly (p < 0.05). HL in subjects without fracture did not differ from those with one fracture (HL 4.8 ± 3.56 vs. 4.8 ± 2.66 cm, respectively). For patients with more than one fracture HL was 7.03 ± 4.06 cm and was significantly higher than in subjects with one or without any fracture (p < 0.01). Based on receiver operating characteristic (ROC) analysis, HL of 6 cm was identified as the cut-off point for high risk of multiple fractures.</p><p><strong>Conclusion: </strong>HL of at least 6 cm is the predictor of multiple fractures in a prospective observation of a representative epidemiological female sample. Therefore, the measurement of HL should always be included in patients' assessments.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab. 使用托西珠单抗治疗皮质类固醇耐药的巴塞杜氏眼病后长期缓解。
Pub Date : 2024-01-01 DOI: 10.5603/ep.97224
Joanna Rymuza, Aleksander Kuś, Dorota Białas-Niedziela, Monika Turczyńska, Dariusz Kęcik, Tomasz Bednarczuk

Not required for Clinical Vignettes.

临床小论文不要求。
{"title":"Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab.","authors":"Joanna Rymuza, Aleksander Kuś, Dorota Białas-Niedziela, Monika Turczyńska, Dariusz Kęcik, Tomasz Bednarczuk","doi":"10.5603/ep.97224","DOIUrl":"10.5603/ep.97224","url":null,"abstract":"<p><p>Not required for Clinical Vignettes.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
p53-associated miRNAs repress lncRNA ZFAS1 to retard the proliferation of papillary thyroid carcinoma. p53相关miRNA抑制lncRNA ZFAS1以延缓甲状腺乳头状癌的增殖。
Pub Date : 2024-01-01 DOI: 10.5603/ep.97567
Gang Wang, Liping Wei, Hui Yang

Introduction: Thyroid carcinoma is the most frequent malignancy among endocrine-related tumours. Papillary thyroid carcinoma (PTC) is the main type of thyroid carcinoma, and almost 80% cases of thyroid carcinoma are diagnosed as PTC. The molecular mechanism underlying PTC progression is unclear. This study aims to investigate the potential mechanisms of zinc finger antisense 1 (ZFAS1) function in PTC.

Material and methods: The expression of ZFAS1 and p53 was determined by quantitative polymerase chain analysis (qPCR) in PTC tissues derived from 20 PTC patients. Quantitative chromatin immunoprecipitation assay (qChIP) analysis was performed to validate the target of ZFAS1/p53 and miRNAs/p53. The Gene Expression Omnibus (GEO) dataset GSE94908 was analysed to obtain the differentially expressed p53-associated microRNAs (miRNAs). Luciferase assay validated the target of ZFAS1/miRNAs, and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cell proliferation.

Results: The expression of ZFAS1 was up-regulated in the tissues derived from PTC patients, and the expression of ZFAS1 was negatively associated with p53 expression in PTC. The expression of ZFAS1 was significantly higher in the MDA-T120 cells harbouring mutant p53. We validated that ZFAS1 is a direct target of p53. In PTC cells, p53 directly repressed the ZFAS1 expression. In addition, we determined that miR-135b-5p and miR-193a-3p are directly induced by p53 in PTC cells. Interestingly, p53-targeted miR-135b-5p, miR-193a-3p, and miR-34b repressed the expression of ZFAS1 via the seed-matching sequences in the 3'-untranslated region (3'-UTR) of ZFAS1, and thereby suppressed PTC cell proliferation induced by ZFAS1.

Conclusion: The oncogenic lncRNA ZFAS1 is directly repressed by p53 in PTC. p53-mediated miRNAs including miR-135b 5p, miR-193a-3p, and miR-34b repress ZFAS1 expression, and thereby inhibit the proliferation of PTC.

简介:甲状腺癌是内分泌相关肿瘤中最常见的恶性肿瘤:甲状腺癌是内分泌相关肿瘤中最常见的恶性肿瘤。甲状腺乳头状癌(PTC)是甲状腺癌的主要类型,近80%的甲状腺癌被诊断为PTC。PTC进展的分子机制尚不清楚。本研究旨在探讨锌指反义1(ZFAS1)在PTC中的潜在作用机制:通过定量聚合酶链分析(qPCR)测定 20 例 PTC 患者 PTC 组织中 ZFAS1 和 p53 的表达。为验证 ZFAS1/p53 和 miRNA/p53 的靶点,进行了染色质免疫沉淀定量分析(qChIP)。对基因表达总库(GEO)数据集 GSE94908 进行了分析,以获得与 p53 相关的差异表达 microRNAs(miRNAs)。荧光素酶检测验证了ZFAS1/miRNAs的靶点,3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)检测用于测定细胞增殖:结果:ZFAS1在PTC患者组织中表达上调,ZFAS1的表达与PTC中p53的表达呈负相关。在携带突变 p53 的 MDA-T120 细胞中,ZFAS1 的表达明显升高。我们验证了 ZFAS1 是 p53 的直接靶标。在 PTC 细胞中,p53 直接抑制 ZFAS1 的表达。此外,我们还发现,在 PTC 细胞中,p53 可直接诱导 miR-135b-5p 和 miR-193a-3p 的表达。有趣的是,p53靶向的miR-135b-5p、miR-193a-3p和miR-34b通过ZFAS1的3'-非翻译区(3'-UTR)中的种子匹配序列抑制了ZFAS1的表达,从而抑制了ZFAS1诱导的PTC细胞增殖:p53介导的miRNA(包括miR-135b 5p、miR-193a-3p和miR-34b)可抑制ZFAS1的表达,从而抑制PTC细胞的增殖。
{"title":"p53-associated miRNAs repress lncRNA ZFAS1 to retard the proliferation of papillary thyroid carcinoma.","authors":"Gang Wang, Liping Wei, Hui Yang","doi":"10.5603/ep.97567","DOIUrl":"10.5603/ep.97567","url":null,"abstract":"<p><strong>Introduction: </strong>Thyroid carcinoma is the most frequent malignancy among endocrine-related tumours. Papillary thyroid carcinoma (PTC) is the main type of thyroid carcinoma, and almost 80% cases of thyroid carcinoma are diagnosed as PTC. The molecular mechanism underlying PTC progression is unclear. This study aims to investigate the potential mechanisms of zinc finger antisense 1 (ZFAS1) function in PTC.</p><p><strong>Material and methods: </strong>The expression of ZFAS1 and p53 was determined by quantitative polymerase chain analysis (qPCR) in PTC tissues derived from 20 PTC patients. Quantitative chromatin immunoprecipitation assay (qChIP) analysis was performed to validate the target of ZFAS1/p53 and miRNAs/p53. The Gene Expression Omnibus (GEO) dataset GSE94908 was analysed to obtain the differentially expressed p53-associated microRNAs (miRNAs). Luciferase assay validated the target of ZFAS1/miRNAs, and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cell proliferation.</p><p><strong>Results: </strong>The expression of ZFAS1 was up-regulated in the tissues derived from PTC patients, and the expression of ZFAS1 was negatively associated with p53 expression in PTC. The expression of ZFAS1 was significantly higher in the MDA-T120 cells harbouring mutant p53. We validated that ZFAS1 is a direct target of p53. In PTC cells, p53 directly repressed the ZFAS1 expression. In addition, we determined that miR-135b-5p and miR-193a-3p are directly induced by p53 in PTC cells. Interestingly, p53-targeted miR-135b-5p, miR-193a-3p, and miR-34b repressed the expression of ZFAS1 via the seed-matching sequences in the 3'-untranslated region (3'-UTR) of ZFAS1, and thereby suppressed PTC cell proliferation induced by ZFAS1.</p><p><strong>Conclusion: </strong>The oncogenic lncRNA ZFAS1 is directly repressed by p53 in PTC. p53-mediated miRNAs including miR-135b 5p, miR-193a-3p, and miR-34b repress ZFAS1 expression, and thereby inhibit the proliferation of PTC.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiofrequency ablation for papillary thyroid microcarcinoma close to the thyroid capsule versus far from the thyroid capsule: a retrospective study. 靠近甲状腺囊与远离甲状腺囊的甲状腺乳头状微癌射频消融术:一项回顾性研究。
Pub Date : 2024-01-01 DOI: 10.5603/ep.95964
Jieli Luo, Tianchen Hui, Peile Jin, Yang Sun, Yajun Chen, Zimei Lin, Pintong Huang

Introduction: The aim of this study was to evaluate the safety and efficacy of ultrasound-guided radiofrequency ablation (RFA) for the management of papillary thyroid microcarcinoma (PTMC) close to the thyroid capsule.

Material and methods: This was a retrospective study of 202 patients with PTMC who underwent RFA close to the thyroid capsule and 80 patients with PTMC who underwent RFA far from the thyroid capsule between June 2015 and December 2022. The follow-up time after RFA, change in size of tumour, location, thyroid function, the rates of PTMC disappearance, and complications were evaluated.

Results: A total of 202 patients with PTMC close to the thyroid capsule and 80 patients with PTMC far from the thyroid capsule successfully treated with RFA were studied. The thyroid function including free triiodothyronine (fT3), free thyroxine (fT4), triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone (TSH) showed no changes after RFA for one months in both groups. The tumour size was increased at 1, 3, and 6 months after RFA compared with pre-operative RFA in both groups. The tumour size was decreased at 12 and 24 months after RFA compared with pre-operative RFA both in both group. Seventy-nine PTMC close to the thyroid capsule and 30 PTMC far from the thyroid capsule completely disappeared as assessed by ultrasound examination. Eighty-four PTMC patients close to the thyroid capsule and 34 PTMC patients far from the thyroid capsule had minor complications after RFA treatment. The complication rates between the 2 groups were similar.

Conclusion: Ultrasound-guided RFA seems to be an effective and safe method for patients with PTMC close to the thyroid capsule.

引言本研究旨在评估超声引导下射频消融术(RFA)治疗靠近甲状腺囊的甲状腺乳头状微小癌(PTMC)的安全性和有效性:这是一项回顾性研究,研究对象为2015年6月至2022年12月期间接受RFA治疗的202例靠近甲状腺囊的PTMC患者和接受RFA治疗的80例远离甲状腺囊的PTMC患者。对RFA术后随访时间、肿瘤大小变化、位置、甲状腺功能、PTMC消失率和并发症进行了评估:共有202名靠近甲状腺囊的PTMC患者和80名远离甲状腺囊的PTMC患者成功接受了RFA治疗。两组患者的甲状腺功能(包括游离三碘甲状腺原氨酸(fT3)、游离甲状腺素(fT4)、三碘甲状腺原氨酸(T3)、甲状腺素(T4)和促甲状腺激素(TSH))在 RFA 治疗 1 个月后均无变化。与术前相比,两组患者在 RFA 术后 1、3 和 6 个月的肿瘤大小均有所增加。与术前相比,两组患者在 RFA 术后 12 个月和 24 个月的肿瘤体积均有所缩小。经超声检查评估,79 例靠近甲状腺囊的 PTMC 和 30 例远离甲状腺囊的 PTMC 完全消失。84名靠近甲状腺囊的PTMC患者和34名远离甲状腺囊的PTMC患者在RFA治疗后出现了轻微并发症。两组患者的并发症发生率相似:结论:对于甲状腺囊附近的PTMC患者来说,超声引导下的RFA似乎是一种有效而安全的方法。
{"title":"Radiofrequency ablation for papillary thyroid microcarcinoma close to the thyroid capsule versus far from the thyroid capsule: a retrospective study.","authors":"Jieli Luo, Tianchen Hui, Peile Jin, Yang Sun, Yajun Chen, Zimei Lin, Pintong Huang","doi":"10.5603/ep.95964","DOIUrl":"10.5603/ep.95964","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to evaluate the safety and efficacy of ultrasound-guided radiofrequency ablation (RFA) for the management of papillary thyroid microcarcinoma (PTMC) close to the thyroid capsule.</p><p><strong>Material and methods: </strong>This was a retrospective study of 202 patients with PTMC who underwent RFA close to the thyroid capsule and 80 patients with PTMC who underwent RFA far from the thyroid capsule between June 2015 and December 2022. The follow-up time after RFA, change in size of tumour, location, thyroid function, the rates of PTMC disappearance, and complications were evaluated.</p><p><strong>Results: </strong>A total of 202 patients with PTMC close to the thyroid capsule and 80 patients with PTMC far from the thyroid capsule successfully treated with RFA were studied. The thyroid function including free triiodothyronine (fT3), free thyroxine (fT4), triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone (TSH) showed no changes after RFA for one months in both groups. The tumour size was increased at 1, 3, and 6 months after RFA compared with pre-operative RFA in both groups. The tumour size was decreased at 12 and 24 months after RFA compared with pre-operative RFA both in both group. Seventy-nine PTMC close to the thyroid capsule and 30 PTMC far from the thyroid capsule completely disappeared as assessed by ultrasound examination. Eighty-four PTMC patients close to the thyroid capsule and 34 PTMC patients far from the thyroid capsule had minor complications after RFA treatment. The complication rates between the 2 groups were similar.</p><p><strong>Conclusion: </strong>Ultrasound-guided RFA seems to be an effective and safe method for patients with PTMC close to the thyroid capsule.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acoustic outcomes and voice-related quality of life in male-to-female transsexuals undergoing Wendler glottoplasty: a single-centre experience. 接受 Wendler 声门成形术的男变女变性人的声学效果和与嗓音相关的生活质量:单中心经验。
Pub Date : 2024-01-01 Epub Date: 2024-03-18 DOI: 10.5603/ep.98899
Maciej Misiołek, Marta Rogalska, Maciej Zieliński, Anna Kasperczuk, Anna Koniewska

Introduction: Many transsexual women seek to feminise their voice through pitch elevation surgeries so that it becomes congruent with their gender identity. This study aims to determine the safety and effectiveness of Wendler glottoplasty (WG) in vocal feminisation through the assessment of acoustic and aerodynamic parameters of the voice, as well as voice-related quality of life (QoL) in male-to-female transsexuals.

Material and methods: We retrospectively reviewed the medical records of transsexual women who underwent WG for voice feminisation at our institution between 2016 and 2023. All acoustic and aerodynamic analyses, a voice self-assessment, and a videolaryngostroboscopic evaluation were performed in the immediate preoperative period and at the follow-up visit 6 weeks after the procedure.

Results: A total of 11 patients with a mean age of 32.73 years were included. After WG, there was a significant fundamental frequency and speaking fundamental frequency increase of 109.64 Hz and 83.48 Hz, respectively (p < 0.001), representing an average rise by 9.71 semitones and 8.36 semitones (STs), respectively. No significant differences were found between the mean pre- and postoperative values of fundamental frequencies, frequency range, upper limit of the frequency range of spoken voice, and maximum phonation time. Contrarily, the mean lower limit of frequency range rose by 75.56 Hz (p < 0.001), representing an average increase of 10.56 STs. None of the assessed spirometric parameters changed significantly after WG (p > 0.05). The mean overall Voice Handicap Index (VHI) and Voice-Related Quality of Life (V-RQOL) scores significantly improved after the surgery, decreasing by 24.54 points (p = 0.008) and 11.5 points (p = 0.001), respectively. A significant improvement was observed in the functional and emotional domains of VHI. Additionally, significantly fewer patients considered the overall quality of their voice to be "poor" after WG.

Conclusions: WG constitutes an effective method of surgical voice feminisation in male-to-female transsexuals with concurrent improvement in their voice-related QoL. Furthermore, it remains a safe procedure without persistent complications and negative influence on the acoustic-aerodynamic measures of the voice.

介绍:许多变性女性都希望通过提高音调的手术来实现嗓音女性化,从而使嗓音与性别认同相一致。本研究旨在通过评估男变女变性者嗓音的声学和空气动力学参数以及与嗓音相关的生活质量(QoL),确定温德勒声门成形术(WG)在嗓音女性化方面的安全性和有效性:我们回顾性地查阅了2016年至2023年期间在本院接受WG嗓音女性化手术的变性女性的病历。所有的声学和空气动力学分析、嗓音自我评估以及视频喉结畸形镜评估均在术前和术后 6 周的随访中进行:共纳入 11 名患者,平均年龄为 32.73 岁。WG 术后,基频和讲基频分别显著增加了 109.64 赫兹和 83.48 赫兹(p < 0.001),平均分别增加了 9.71 个半音和 8.36 个半音(STs)。术前和术后的基频平均值、频率范围、语音频率范围上限和最大发音时间均无明显差异。相反,频率范围的平均下限上升了 75.56 Hz(p < 0.001),平均增加了 10.56 STs。经过 WG 评估后,肺活量参数均无明显变化(P > 0.05)。术后,嗓音障碍指数(VHI)和嗓音相关生活质量(V-RQOL)的平均总分明显改善,分别降低了 24.54 分(p = 0.008)和 11.5 分(p = 0.001)。在 VHI 的功能和情感领域都有明显改善。此外,经过 WG 治疗后,认为嗓音整体质量 "差 "的患者明显减少:WG是男变女变性患者进行嗓音女性化手术的有效方法,同时还能改善他们与嗓音相关的生活质量。此外,WG 仍然是一种安全的手术,不会出现持续性并发症,也不会对嗓音的声学空气动力学指标产生负面影响。
{"title":"Acoustic outcomes and voice-related quality of life in male-to-female transsexuals undergoing Wendler glottoplasty: a single-centre experience.","authors":"Maciej Misiołek, Marta Rogalska, Maciej Zieliński, Anna Kasperczuk, Anna Koniewska","doi":"10.5603/ep.98899","DOIUrl":"10.5603/ep.98899","url":null,"abstract":"<p><strong>Introduction: </strong>Many transsexual women seek to feminise their voice through pitch elevation surgeries so that it becomes congruent with their gender identity. This study aims to determine the safety and effectiveness of Wendler glottoplasty (WG) in vocal feminisation through the assessment of acoustic and aerodynamic parameters of the voice, as well as voice-related quality of life (QoL) in male-to-female transsexuals.</p><p><strong>Material and methods: </strong>We retrospectively reviewed the medical records of transsexual women who underwent WG for voice feminisation at our institution between 2016 and 2023. All acoustic and aerodynamic analyses, a voice self-assessment, and a videolaryngostroboscopic evaluation were performed in the immediate preoperative period and at the follow-up visit 6 weeks after the procedure.</p><p><strong>Results: </strong>A total of 11 patients with a mean age of 32.73 years were included. After WG, there was a significant fundamental frequency and speaking fundamental frequency increase of 109.64 Hz and 83.48 Hz, respectively (p < 0.001), representing an average rise by 9.71 semitones and 8.36 semitones (STs), respectively. No significant differences were found between the mean pre- and postoperative values of fundamental frequencies, frequency range, upper limit of the frequency range of spoken voice, and maximum phonation time. Contrarily, the mean lower limit of frequency range rose by 75.56 Hz (p < 0.001), representing an average increase of 10.56 STs. None of the assessed spirometric parameters changed significantly after WG (p > 0.05). The mean overall Voice Handicap Index (VHI) and Voice-Related Quality of Life (V-RQOL) scores significantly improved after the surgery, decreasing by 24.54 points (p = 0.008) and 11.5 points (p = 0.001), respectively. A significant improvement was observed in the functional and emotional domains of VHI. Additionally, significantly fewer patients considered the overall quality of their voice to be \"poor\" after WG.</p><p><strong>Conclusions: </strong>WG constitutes an effective method of surgical voice feminisation in male-to-female transsexuals with concurrent improvement in their voice-related QoL. Furthermore, it remains a safe procedure without persistent complications and negative influence on the acoustic-aerodynamic measures of the voice.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of anti-Müllerian hormone and insulin resistance in adolescent girls with polycystic ovary syndrome. 多囊卵巢综合征少女体内抗缪勒氏管激素与胰岛素抵抗的关系。
Pub Date : 2024-01-01 DOI: 10.5603/ep.96323
Gang Guo, Huan Zheng, Xia Wu

Introduction: Insulin resistance (IR) is confirmed as an important feature among polycystic ovary syndrome (PCOS) patients. Anti-Müllerian hormone (AMH), a vital marker of ovarian dysfunction, is proposed for inclusion in the diagnosis of PCOS in adolescents. We sought to investigate the relationship between the AMH level and IR in Chinese girls with PCOS.

Material and methods: 92 girls with PCOS aged 14-18 years were enrolled and divided into 2 subgroups: PCOS with IR group (n = 25) and PCOS without IR group (n = 67). A homeostasis model assessment-insulin resistance (HOMA-IR) value ≥ 2.5 was defined as IR. Clinical data and biochemical indexes were compared between the 2 groups. Multivariate logistic regression analysis and multivariate linear regression analysis were performed to determine which clinical variables were independently associated with IR and AMH level, respectively.

Results: PCOS girls with IR had higher levels of AMH than those of PCOS girls without IR (p < 0.01). Moreover, body mass index, triglyceride, and AMH values were shown to be independent risk factors for HOMA-IR after multivariate analysis. Meanwhile, age, insulin, and follicle-stimulating hormone levels were significantly related to AMH levels in those girls.

Conclusions: Our findings show that AMH is an independent determinant of IR in PCOS adolescents, and the fasting insulin level is closely associated with the AMH level, which indicates that the AMH pathway might play a role in the development of IR in PCOS adolescents. The interaction between AMH and IR in PCOS girls warrants further large-scale evaluation.

引言胰岛素抵抗(IR)已被证实是多囊卵巢综合征(PCOS)患者的一个重要特征。抗缪勒氏管激素(AMH)是卵巢功能障碍的重要标志物,被建议纳入青少年多囊卵巢综合征的诊断中。我们试图研究中国多囊卵巢综合征女孩的 AMH 水平与 IR 之间的关系。材料和方法:我们招募了 92 名 14-18 岁的多囊卵巢综合征女孩,并将其分为 2 个亚组:材料:92名14-18岁的多囊卵巢综合征女孩,分为两组:多囊卵巢综合征伴IR组(25人)和多囊卵巢综合征非IR组(67人)。稳态模型评估-胰岛素抵抗(HOMA-IR)值≥2.5定义为IR。对两组患者的临床数据和生化指标进行比较。分别进行了多变量逻辑回归分析和多变量线性回归分析,以确定哪些临床变量与IR和AMH水平独立相关:结果:有IR的多囊卵巢综合征女孩的AMH水平高于无IR的多囊卵巢综合征女孩(P<0.01)。此外,多变量分析表明,体重指数、甘油三酯和 AMH 值是 HOMA-IR 的独立危险因素。同时,年龄、胰岛素和卵泡刺激素水平与这些女孩的 AMH 水平有显著关系:结论:我们的研究结果表明,AMH是多囊卵巢综合征青少年IR的独立决定因素,空腹胰岛素水平与AMH水平密切相关,这表明AMH途径可能在多囊卵巢综合征青少年IR的发展中发挥作用。多囊卵巢综合征女孩体内AMH与IR之间的相互作用值得进一步进行大规模评估。
{"title":"Association of anti-Müllerian hormone and insulin resistance in adolescent girls with polycystic ovary syndrome.","authors":"Gang Guo, Huan Zheng, Xia Wu","doi":"10.5603/ep.96323","DOIUrl":"10.5603/ep.96323","url":null,"abstract":"<p><strong>Introduction: </strong>Insulin resistance (IR) is confirmed as an important feature among polycystic ovary syndrome (PCOS) patients. Anti-Müllerian hormone (AMH), a vital marker of ovarian dysfunction, is proposed for inclusion in the diagnosis of PCOS in adolescents. We sought to investigate the relationship between the AMH level and IR in Chinese girls with PCOS.</p><p><strong>Material and methods: </strong>92 girls with PCOS aged 14-18 years were enrolled and divided into 2 subgroups: PCOS with IR group (n = 25) and PCOS without IR group (n = 67). A homeostasis model assessment-insulin resistance (HOMA-IR) value ≥ 2.5 was defined as IR. Clinical data and biochemical indexes were compared between the 2 groups. Multivariate logistic regression analysis and multivariate linear regression analysis were performed to determine which clinical variables were independently associated with IR and AMH level, respectively.</p><p><strong>Results: </strong>PCOS girls with IR had higher levels of AMH than those of PCOS girls without IR (p < 0.01). Moreover, body mass index, triglyceride, and AMH values were shown to be independent risk factors for HOMA-IR after multivariate analysis. Meanwhile, age, insulin, and follicle-stimulating hormone levels were significantly related to AMH levels in those girls.</p><p><strong>Conclusions: </strong>Our findings show that AMH is an independent determinant of IR in PCOS adolescents, and the fasting insulin level is closely associated with the AMH level, which indicates that the AMH pathway might play a role in the development of IR in PCOS adolescents. The interaction between AMH and IR in PCOS girls warrants further large-scale evaluation.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
STAR gene mutation in a patient with congenital lipoid adrenal hyperplasia. 一名先天性类脂性肾上腺皮质增生症患者的 STAR 基因突变。
Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.5603/ep.99040
Yan Zhang, Chunying Song, Lei Zhang, Lixin Shi, Qiao Zhang

Not required for Clinical Vignette.

临床小论文不需要。
{"title":"STAR gene mutation in a patient with congenital lipoid adrenal hyperplasia.","authors":"Yan Zhang, Chunying Song, Lei Zhang, Lixin Shi, Qiao Zhang","doi":"10.5603/ep.99040","DOIUrl":"10.5603/ep.99040","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron and ferritin deficiency in women with hypothyroidism and chronic lymphocytic thyroiditis - systematic review. 甲状腺功能减退症和慢性淋巴细胞性甲状腺炎妇女的铁和铁蛋白缺乏症--系统综述。
Pub Date : 2024-01-01 Epub Date: 2024-06-26 DOI: 10.5603/ep.97860
Marcin Gierach, Monika Rudewicz, Roman Junik

Iron is one of the essential microelements necessary for maintaining the body's homeostasis. It serves various roles, including being a crucial component in the proper structure of many enzymes and supporting the transport of oxygen and electrons. Its deficiency can lead to anaemia, which is a common clinical condition often associated with thyroid diseases. Iron deficiency is one of the most common nutritional deficiencies, and its prevalence is strongly associated with socioeconomic status. It is the primary cause of anaemia in 42% of children and 50% of women. Importantly, iron deficiency is placed among the top 5 causes of disability in women. Thyroid peroxidase (TPO) is an enzyme essential for the production of thyroid hormones, and iron is a key factor in its proper functioning. Therefore, in the case of iron deficiency, the activity of this enzyme is also reduced. Iron is also a factor that is important in epigenetic modification processes, and its deficiency may contribute to genomic changes potentially promoting the development of autoimmune thyroid diseases. Adequate supplementation in patients with Hashimoto's disease is one of the crucial elements of effective therapy. In addition to iodine, selenium, and magnesium supplementation, attention should be paid to proper iron intake. Iron is an element that is a component of the heme enzyme- thyroid peroxidase, which owes its activity to the binding of haem, and its function is the production of thyroid hormones. Iron can be delivered to the body in haem and non-haem forms. The haem form is found particularly in haemoglobin-rich red meat, but also in eggs, fish, and poultry. On the other hand, non-haem iron can be found in legumes, grains, fruits, and vegetables. Our study aimed to gather and summarise knowledge from scientific literature regarding iron deficiency anaemia and its association with hypothyroidism in women, as well as the possible mechanisms and pathogenesis of these conditions. The paper also aims to highlight that considering the high risk of iron deficiency, assessing iron status along with ferritin should be an integral part of additional diagnostic measures in cases of hypothyroidism, particularly Hashimoto's disease.

铁是维持人体平衡所必需的微量元素之一。它有多种作用,包括作为许多酶正常结构的重要组成部分,以及支持氧和电子的运输。缺铁会导致贫血,而贫血是一种常见的临床症状,通常与甲状腺疾病有关。缺铁是最常见的营养缺乏症之一,其发病率与社会经济地位密切相关。42%的儿童和50%的妇女贫血的主要原因就是缺铁。重要的是,缺铁是导致妇女残疾的五大原因之一。甲状腺过氧化物酶(TPO)是产生甲状腺激素所必需的一种酶,而铁是其正常运作的关键因素。因此,在缺铁的情况下,这种酶的活性也会降低。铁也是表观遗传修饰过程中的一个重要因素,缺铁可能会导致基因组变化,从而诱发自身免疫性甲状腺疾病。对桥本氏病患者进行充分补充是有效治疗的关键因素之一。除了补充碘、硒和镁之外,还应注意适当摄入铁。铁是血红素酶--甲状腺过氧化物酶的一种成分,它的活性归功于与血红素的结合,其功能是产生甲状腺激素。铁可以血红素和非血红素两种形式进入人体。血红素形式主要存在于富含血红素的红肉中,也存在于鸡蛋、鱼和家禽中。而非血红素铁则存在于豆类、谷物、水果和蔬菜中。我们的研究旨在收集和总结科学文献中有关女性缺铁性贫血及其与甲状腺功能减退症的关系的知识,以及这些病症的可能机制和发病机理。本文还旨在强调,考虑到缺铁的高风险,在甲状腺功能减退症(尤其是桥本氏病)的额外诊断措施中,应将评估铁状况和铁蛋白作为不可或缺的一部分。
{"title":"Iron and ferritin deficiency in women with hypothyroidism and chronic lymphocytic thyroiditis - systematic review.","authors":"Marcin Gierach, Monika Rudewicz, Roman Junik","doi":"10.5603/ep.97860","DOIUrl":"10.5603/ep.97860","url":null,"abstract":"<p><p>Iron is one of the essential microelements necessary for maintaining the body's homeostasis. It serves various roles, including being a crucial component in the proper structure of many enzymes and supporting the transport of oxygen and electrons. Its deficiency can lead to anaemia, which is a common clinical condition often associated with thyroid diseases. Iron deficiency is one of the most common nutritional deficiencies, and its prevalence is strongly associated with socioeconomic status. It is the primary cause of anaemia in 42% of children and 50% of women. Importantly, iron deficiency is placed among the top 5 causes of disability in women. Thyroid peroxidase (TPO) is an enzyme essential for the production of thyroid hormones, and iron is a key factor in its proper functioning. Therefore, in the case of iron deficiency, the activity of this enzyme is also reduced. Iron is also a factor that is important in epigenetic modification processes, and its deficiency may contribute to genomic changes potentially promoting the development of autoimmune thyroid diseases. Adequate supplementation in patients with Hashimoto's disease is one of the crucial elements of effective therapy. In addition to iodine, selenium, and magnesium supplementation, attention should be paid to proper iron intake. Iron is an element that is a component of the heme enzyme- thyroid peroxidase, which owes its activity to the binding of haem, and its function is the production of thyroid hormones. Iron can be delivered to the body in haem and non-haem forms. The haem form is found particularly in haemoglobin-rich red meat, but also in eggs, fish, and poultry. On the other hand, non-haem iron can be found in legumes, grains, fruits, and vegetables. Our study aimed to gather and summarise knowledge from scientific literature regarding iron deficiency anaemia and its association with hypothyroidism in women, as well as the possible mechanisms and pathogenesis of these conditions. The paper also aims to highlight that considering the high risk of iron deficiency, assessing iron status along with ferritin should be an integral part of additional diagnostic measures in cases of hypothyroidism, particularly Hashimoto's disease.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Endokrynologia Polska
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1